Latest Posts
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...
The Expanding Reach of the European Patent Office. Good for Health?
The European Patent Office (EPO) is tasked with the examination of patent applications and the granting of patents when these applications meet the patentability...
Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
This work is licensed under